Ligand Pharmaceuticals | LGND - Cash And Equivalent


Ligand Pharmaceuticals reported $1.01B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Enviri Corporation USD 105.7M 2.03M Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Pfizer USD 976M 727M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 299.52M 36.38M Jun/2026